Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3B BlackBio DxBOM:532067 -0.34%64 3-Year ROIIC % is 16.13 as of Mar. 2026, which is 13% below its 10-year median of 18.51. GuruFocus rates BOM:532067 with a GF Score™ of 64/100 and a GF Value™ of ₹2,199.23 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,315 Biotechnology companies, 3B BlackBio Dx ranks better than 63.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
3B BlackBio Dx's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 16.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for 3B BlackBio Dx's 3-Year ROIIC % or its related term are showing as below:
BOM:532067's 3-Year ROIIC % is ranked better than 63.5% of 1315
companies
in the Biotechnology industry
Industry Median: -4.82
vs BOM:532067: 16.13
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
3B BlackBio Dx 3-Year ROIIC % Related Terms
3B BlackBio Dx 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for 3B BlackBio Dx's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532067 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, 3B BlackBio Dx's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3B BlackBio Dx 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3B BlackBio Dx's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where 3B BlackBio Dx's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
3B BlackBio Dx (BOM:532067) has a 3-Year ROIIC % of 16.13 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 3B BlackBio Dx and its competitors. This is 13% below median its historical median of 18.51. According to the industry distribution chart, 3B BlackBio Dx ranks #480 out of 1315 companies in the Biotechnology industry, placing it in the top 36.5%.
Is 3B BlackBio Dx's 3-Year ROIIC % too high?
3B BlackBio Dx's current 3-Year ROIIC % of 16.13 is 13% below median its 10-year median of 18.51. Based on the distribution chart, 3B BlackBio Dx ranks #480 out of 1315 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3B BlackBio Dx has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3B BlackBio Dx's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3B BlackBio Dx ranks #480 out of 1315 companies for 3-Year ROIIC %. This puts 3B BlackBio Dx in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 3B BlackBio Dx and its competitors. 3B BlackBio Dx's current 3-Year ROIIC % is 16.13, which is 13% below median its own 10-year median of 18.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3B BlackBio Dx stock overvalued right now?
Based on GuruFocus' analysis, 3B BlackBio Dx (BOM:532067) is currently considered Possible Value Trap. The stock's GF Value™ is ₹2,199.23, compared to a current price of ₹1,262.20 — trading 42.6% below its estimated fair value. The current 3-Year ROIIC % is 16.13, which is 13% below median its 10-year median of 18.51. 3B BlackBio Dx's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For 3B BlackBio Dx (BOM:532067), the current 3-Year ROIIC % is 16.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3B BlackBio Dx (BOM:532067) Overvalued in 2026?
Based on GuruFocus' analysis, 3B BlackBio Dx stock appears to be undervalued.
The current stock price of ₹1,262.20 is trading 42.6% below its estimated GF Value™ of ₹2,199.23.
GuruFocus considers 3B BlackBio Dx to be Possible Value Trap.
Key valuation signals for BOM:532067:
3-Year ROIIC %: 16.13 (13% below median its 10-year median of 18.51)
GF Value™: ₹2,199.23 vs. price of ₹1,262.20 (42.6% below fair value)
No single metric tells the full story. See the BOM:532067 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3B BlackBio Dx Ltd is an Indian company specializing in PCR-based Molecular Diagnostic Kits. The company is involved in designing, developing, manufacturing, and commercializing PCR-based Molecular Diagnostic kits, PCR Enzymes, and PCR Reagents.
64GF Score
Get the complete analysis for BOM:532067
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532067 has been successfully added to your 
